LARGE B-CELL LYMPHOMA
Clinical trials for LARGE B-CELL LYMPHOMA explained in plain language.
Never miss a new study
Get alerted when new LARGE B-CELL LYMPHOMA trials appear
Sign up with your email to follow new studies for LARGE B-CELL LYMPHOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Major trial aims to boost chemo power against aggressive blood cancer
Disease control OngoingThis large, late-stage study is testing whether adding an experimental drug called golcadomide to standard chemotherapy (R-CHOP) works better and is safe for people newly diagnosed with high-risk large B-cell lymphoma. It will involve about 850 participants who will be randomly a…
Matched conditions: LARGE B-CELL LYMPHOMA
Phase: PHASE3 • Sponsor: Celgene • Aim: Disease control
Last updated Mar 27, 2026 12:39 UTC
-
New hope for Tough-to-Treat lymphoma: Two-Drug combo enters final testing phase
Disease control OngoingThis study is testing the safety and effectiveness of a two-drug combination (tafasitamab plus lenalidomide) for adults with an aggressive type of blood cancer called diffuse large B-cell lymphoma (DLBCL). It is for people whose cancer has returned or did not respond to 1 to 3 pr…
Matched conditions: LARGE B-CELL LYMPHOMA
Phase: PHASE3 • Sponsor: Incyte Corporation • Aim: Disease control
Last updated Mar 27, 2026 12:39 UTC
-
New 'Living Drug' trial targets tough blood cancers after other treatments fail
Disease control OngoingThis study is testing a new type of personalized immune cell therapy called rapcabtagene autoleucel (a CAR-T cell therapy) for adults with several aggressive or returning blood cancers. The main goals are to find a safe and effective dose and to see if the therapy can shrink or e…
Matched conditions: LARGE B-CELL LYMPHOMA
Phase: PHASE1, PHASE2 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Mar 24, 2026 12:02 UTC
-
Major trial aims to boost First-Line fight against aggressive lymphoma
Disease control OngoingThis large, late-stage study is testing if adding a new immunotherapy drug called glofitamab to a standard chemotherapy regimen works better for people newly diagnosed with a fast-growing type of lymphoma. It will involve over 1,100 participants to see if the new combination help…
Matched conditions: LARGE B-CELL LYMPHOMA
Phase: PHASE3 • Sponsor: Hoffmann-La Roche • Aim: Disease control
Last updated Mar 24, 2026 12:02 UTC
-
Off-the-Shelf immune cell therapy tested in Tough-to-Treat lymphoma
Disease control OngoingThis is a first-in-human study to test the safety of a new type of 'off-the-shelf' immune cell therapy called SC262. It is for adults with non-Hodgkin's lymphoma whose cancer has come back or stopped responding to treatment, including a prior CAR-T therapy. The main goal is to fi…
Matched conditions: LARGE B-CELL LYMPHOMA
Phase: PHASE1 • Sponsor: Sana Biotechnology • Aim: Disease control
Last updated Mar 23, 2026 15:15 UTC
-
New hope for lymphoma patients Who've run out of options
Disease control OngoingThis early-stage study is testing whether adding a new immunotherapy drug called mosunetuzumab to standard chemotherapy is safe and effective for adults with aggressive B-cell lymphoma that has returned or not responded to prior treatment. The trial will enroll 24 participants to…
Matched conditions: LARGE B-CELL LYMPHOMA
Phase: PHASE1 • Sponsor: Washington University School of Medicine • Aim: Disease control
Last updated Mar 17, 2026 13:09 UTC
-
Engineered immune cells battle advanced blood cancers in new trial
Disease control OngoingThis study is testing several FDA-approved CAR-T cell therapies for patients whose blood cancers have returned or not responded to standard treatments. It involves about 150 participants with conditions like acute lymphoblastic leukemia and various lymphomas. The main goals are t…
Matched conditions: LARGE B-CELL LYMPHOMA
Phase: PHASE2 • Sponsor: Masonic Cancer Center, University of Minnesota • Aim: Disease control
Last updated Feb 27, 2026 15:20 UTC
-
New scan could predict if cancer treatment will work
Knowledge-focused OngoingThis study is testing a new type of PET scan to see if it can help doctors predict which patients with large B-cell lymphoma will respond well to CAR-T cell therapy. Researchers will use a special imaging tracer to look for a specific protein (PD-L1) in the body before treatment.…
Matched conditions: LARGE B-CELL LYMPHOMA
Phase: PHASE2 • Sponsor: University Medical Center Groningen • Aim: Knowledge-focused
Last updated Mar 25, 2026 14:09 UTC